TraceLink, the World’s Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announced that FAREVA has selected TraceLink’s serialization solutions to ensure compliance with the EU Falsified Medicines Directive (FMD).
A global pharmaceutical and API leading contract development and manufacturing organization (CDMO), FAREVA produces various dosage forms and API as well as offers packing options. With over 1,000 customers, FAREVA operates 35 sites across Europe, Russia, Turkey and The Americas.
As a leading global CDMO, FAREVA needed a serialization solution that could not only ensure compliance ahead of the February 2019 deadline, but one that enabled successful data exchange. TraceLink was selected because of its network-tenant platform and its proven ability to facilitate fast and comprehensive integration to CDMOs, allowing FAREVA to connect with its pharmaceutical customers.
Sebastien Poncet, Vice-President of Sales at FAREVA, commented:
“Serialization impacts every aspect of the pharmaceutical supply chain, and as a CDMO, we recognize the critical role we play in regard to industry preparedness. After a thorough evaluation, TraceLink stood out as the only provider who had a solution that would eliminate the time-intensive and cost prohibitive task of point-to-point connections, while also allowing us to streamline data exchange with our customers and support them in being compliant with serialization regulations.”
More than 500 CMOs are fully-configured on the TraceLink Life Sciences Cloud and ready to exchange serialization data.
Headquartered in North Reading, Massachusetts (USA), TraceLink develops and offers track and trace network solution for connecting the life sciences supply chain and eliminating counterfeit prescription drugs. The company offers pharmaceutical serialization, drug tracking and tracing compliance, and supply network performance solutions.